Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyScopolamine butylbromide
Identification
- Name
- Scopolamine butylbromide
- Accession Number
- DB09300 (DB11535)
- Type
- Small Molecule
- Groups
- Approved, Vet Approved
- Description
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.
- Structure
Structure for DB09300 (Scopolamine butylbromide)
- Synonyms
- [7(S)-(1α,2β,4β,5α,7β)]-9-butyl-7-(3-hydroxy- 1-oxo-2-phenylpropoxy)-9-methyl-3-oxa- 9-azonitricyclo[3.3.1.0(2,4)]nonane
- Butylhyoscine
- Butylscopolamine
- Butylscopolamine bromide
- Butylscopolaminebromide
- Hyoscine butylbromide
- N-butylscopolammonium bromide
- Scopolamine bromobutylate
- Scopolamine N-butylbromide
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Buscopan Liquid 20 mg Intramuscular; Intravenous; Subcutaneous Sanofi Aventis 1976-12-31 Not applicable Canada 
Buscopan Tablet 10 mg Oral Sanofi Aventis 1976-12-31 Not applicable Canada Buscopan Sup 10mg Suppository 10 mg Rectal Boehringer Ingelheim (Canada) Ltd Ltee 1976-12-31 2001-07-30 Canada Hyoscine Butylbromide Injection Sandoz Standard Solution 20 mg Intramuscular; Intravenous; Subcutaneous Sandoz Canada Incorporated 1997-08-25 Not applicable Canada - Categories
- Alimentary Tract and Metabolism
- Alkaloids
- Amines
- Ammonium Compounds
- Autonomic Agents
- Aza Compounds
- Azabicyclo Compounds
- Cholinergic Agents
- Cholinergic Antagonists
- Drugs for Functional Gastrointestinal Disorders
- Muscarinic Antagonists
- Neurotransmitter Agents
- Nitrogen Compounds
- Onium Compounds
- Parasympatholytics
- Peripheral Nervous System Agents
- Quaternary Ammonium Compounds
- Scopolamine Derivatives
- Tropanes
- UNII
- 0GH9JX37C8
- CAS number
- 149-64-4
- Weight
- Average: 440.371
Monoisotopic: 439.1358211 - Chemical Formula
- C21H30BrNO4
- InChI Key
- HOZOZZFCZRXYEK-GSWUYBTGSA-M
- InChI
- InChI=1S/C21H30NO4.BrH/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14;/h5-9,15-20,23H,3-4,10-13H2,1-2H3;1H/q+1;/p-1/t15-,16-,17-,18+,19-,20+,22?;/m1./s1
- IUPAC Name
- (1R,2R,4S,5S,7R)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-9-ium bromide
- SMILES
- [Br-].CCCC[N+]1(C)[[email protected]]2C[[email protected]@H](C[[email protected]@H]1[[email protected]]1O[[email protected]@H]21)OC(=O)[[email protected]](CO)C1=CC=CC=C1
Pharmacology
- Indication
Used to treat abdmoninal cramping and pain [FDA Label].
- Structured Indications
- Pharmacodynamics
Scopolamine butylbromide is a muscarinic antagonist which acts to prevent acetylcholine-stimulated contraction of smooth muscle in the gastrointestinal tract [1].
- Mechanism of action
Scopolamine butylbromide binds to muscarinic M3 receptors in the gastrointestinal tract [1]. This prevents acetycholine from binding to and activating the receptors which would result in contraction of the smooth muscle. The inhibition of contraction reduces spasms and their related pain during abdominal cramping.
Target Actions Organism AMuscarinic acetylcholine receptor M3 antagonistHuman UMuscarinic acetylcholine receptor M2 antagonistHuman - Absorption
Scopolamine butylbromide has extremely low oral bioavailability with only 0.25-0.82% reaching systemic circulation [1]. Peak plasma concentration is reached 0.25-2 hours. Scopolamine butylbromide does not cross the blood brain barrier.
- Volume of distribution
The volume of distribution is 128 liters [1].
- Protein binding
- Not Available
- Metabolism
Metabolism occurs mainly through hydrolysis of the ester bond [1]. The metabolites are not considered to be significantly active.
- Route of elimination
Mainly eliminated in the feces (69.7%) with very little in the urine (4.4%) [1]. Only 2.8% is eliminated via the bile owing to scopolamine butylbromide's poor absorption.
- Half life
The half life of elimination is 1-5 hours [1].
- Clearance
Total clearace is 1.2 liters per minute [1].
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with 1,10-Phenanthroline. Experimental Aclidinium Aclidinium may increase the anticholinergic activities of Scopolamine butylbromide. Approved Alcuronium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alcuronium. Experimental Alfentanil The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alfentanil. Approved, Illicit Alphacetylmethadol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alphaprodine. Illicit Ambenonium The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ambenonium. Approved Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Scopolamine butylbromide. Approved Atracurium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Atracurium. Experimental Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine butylbromide. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine butylbromide. Approved, Vet Approved Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Scopolamine butylbromide. Withdrawn Bendroflumethiazide The serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine butylbromide. Approved Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine butylbromide. Approved Bezitramide The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Bezitramide. Experimental, Illicit, Withdrawn Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Scopolamine butylbromide. Approved Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Scopolamine butylbromide. Experimental Botulinum Toxin Type A Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type B. Approved Buprenorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Butorphanol. Approved, Illicit, Vet Approved Carfentanil The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Carfentanil. Illicit, Vet Approved Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide. Approved, Vet Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Scopolamine butylbromide. Withdrawn Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine butylbromide. Approved Cimetropium Scopolamine butylbromide may increase the anticholinergic activities of Cimetropium. Experimental Codeine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Codeine. Approved, Illicit Coumaphos The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Coumaphos. Vet Approved Cyclopenthiazide The serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine butylbromide. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Scopolamine butylbromide. Approved Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine butylbromide. Approved, Investigational Decamethonium The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Decamethonium. Approved Demecarium The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Demecarium. Approved Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Scopolamine butylbromide. Approved, Investigational Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Scopolamine butylbromide. Withdrawn Dextromoramide The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dezocine. Approved Dichlorvos The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Dichlorvos. Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Scopolamine butylbromide. Approved Dihydrocodeine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydromorphine. Experimental, Illicit Diphenoxylate The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Diphenoxylate. Approved, Illicit Distigmine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Distigmine. Experimental Donepezil The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Donepezil. Approved DPDPE The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with DPDPE. Investigational Dronabinol Scopolamine butylbromide may increase the tachycardic activities of Dronabinol. Approved, Illicit Echothiophate The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Echothiophate. Approved Edrophonium The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Edrophonium. Approved Eluxadoline Scopolamine butylbromide may increase the constipating activities of Eluxadoline. Approved Emepronium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Emepronium. Experimental Etanautine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etanautine. Experimental Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine butylbromide. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ethylmorphine. Approved, Illicit Etorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etorphine. Illicit, Vet Approved Etybenzatropine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etybenzatropine. Experimental Fentanyl The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenthion The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Fenthion. Vet Approved Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Scopolamine butylbromide. Approved Galantamine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Galantamine. Approved Gallamine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Gallamine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Scopolamine butylbromide. Approved Ginkgo biloba The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ginkgo biloba. Approved, Nutraceutical Glucagon recombinant The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Glucagon recombinant. Approved Glycopyrronium Scopolamine butylbromide may increase the anticholinergic activities of Glycopyrronium. Approved, Investigational, Vet Approved Heroin The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Heroin. Approved, Illicit Hexamethonium The risk or severity of adverse effects can be increased when Hexamethonium is combined with Scopolamine butylbromide. Experimental Homatropine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Homatropine. Approved Huperzine A The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Huperzine A. Investigational Hydrochlorothiazide The serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine butylbromide. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydrocodone. Approved, Illicit Hydroflumethiazide The serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine butylbromide. Approved Hydromorphone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydromorphone. Approved, Illicit Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine butylbromide. Approved Indapamide The serum concentration of Indapamide can be increased when it is combined with Scopolamine butylbromide. Approved Ipidacrine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ipidacrine. Experimental Ipratropium bromide The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine butylbromide. Approved Isoflurophate The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Isoflurophate. Approved, Withdrawn Itopride The therapeutic efficacy of Itopride can be decreased when used in combination with Scopolamine butylbromide. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ketobemidone. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levomethadyl Acetate. Approved Levorphanol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levorphanol. Approved Lofentanil The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Lofentanil. Illicit Malathion The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Malathion. Approved, Investigational Mazaticol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mazaticol. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine butylbromide. Approved Mefloquine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Mefloquine. Approved Memantine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Memantine. Approved, Investigational Meptazinol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Meptazinol. Experimental Methadone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadyl Acetate. Approved, Illicit Methanesulfonyl Fluoride The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Methanesulfonyl Fluoride. Investigational Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Scopolamine butylbromide. Approved Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine butylbromide. Approved Methyl salicylate The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Methyl salicylate. Approved, Vet Approved Metixene The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Metixene. Approved Metoclopramide The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Metoclopramide. Approved, Investigational Metolazone The serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide. Approved Mianserin Mianserin may increase the anticholinergic activities of Scopolamine butylbromide. Approved Minaprine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Minaprine. Approved Mirabegron The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mirabegron. Approved Morphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Morphine. Approved, Investigational Nabilone Scopolamine butylbromide may increase the tachycardic activities of Nabilone. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nalbuphine. Approved Neostigmine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Neostigmine. Approved, Vet Approved Nicomorphine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nicomorphine. Experimental Normethadone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Normethadone. Approved, Illicit Opium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Opium. Approved, Illicit Orphenadrine The risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine butylbromide. Approved Otilonium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Otilonium. Experimental Oxitropium The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxitropium. Investigational Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Scopolamine butylbromide. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxymorphone. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Scopolamine butylbromide. Approved Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Scopolamine butylbromide. Approved Paraoxon The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Paraoxon. Experimental Pentazocine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pentazocine. Approved, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Scopolamine butylbromide. Approved Pethidine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Phenazocine. Experimental Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Scopolamine butylbromide. Experimental Phenoperidine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Phenoperidine. Experimental Physostigmine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Physostigmine. Approved Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Scopolamine butylbromide. Approved Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine butylbromide. Approved Piritramide The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Piritramide. Investigational Polythiazide The serum concentration of Polythiazide can be increased when it is combined with Scopolamine butylbromide. Approved Potassium Chloride Scopolamine butylbromide may increase the ulcerogenic activities of Potassium Chloride. Approved, Withdrawn Pramlintide Pramlintide may increase the anticholinergic activities of Scopolamine butylbromide. Approved, Investigational Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine butylbromide. Approved Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Scopolamine butylbromide. Approved Propiverine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Propiverine. Investigational Pyridostigmine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Pyridostigmine. Approved Quinethazone The serum concentration of Quinethazone can be increased when it is combined with Scopolamine butylbromide. Approved Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Scopolamine butylbromide. Approved Ramosetron Scopolamine butylbromide may increase the constipating activities of Ramosetron. Approved Remifentanil The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Remifentanil. Approved Rivastigmine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Rivastigmine. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Scopolamine butylbromide. Approved Secretin The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide. Approved, Investigational Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Scopolamine butylbromide. Approved Sufentanil The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil. Approved, Investigational Sulpiride The therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine butylbromide. Approved Tacrine The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Tacrine. Withdrawn Tapentadol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tapentadol. Approved Tilidine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tilidine. Experimental Tiotropium Scopolamine butylbromide may increase the anticholinergic activities of Tiotropium. Approved Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Scopolamine butylbromide. Approved, Investigational Topiramate The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tramadol. Approved, Investigational Trichlorfon The therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Trichlorfon. Vet Approved Trichlormethiazide The serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine butylbromide. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine butylbromide. Approved Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Scopolamine butylbromide. Approved Tropatepine The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tropatepine. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Scopolamine butylbromide. Approved Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Scopolamine butylbromide. Approved Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Scopolamine butylbromide. Approved Umeclidinium Umeclidinium may increase the anticholinergic activities of Scopolamine butylbromide. Approved Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Scopolamine butylbromide. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
- Not Available
- General References
- Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]
- External Links
- KEGG Drug
- D01451
- PubChem Compound
- 6852391
- PubChem Substance
- 310265192
- ChemSpider
- 16736107
- ChEMBL
- CHEMBL1256901
- Wikipedia
- Butylscopolamine
- ATC Codes
- A03BB01 — Butylscopolamine
- A03BB — Belladonna alkaloids, semisynthetic, quaternary ammonium compounds
- A03B — BELLADONNA AND DERIVATIVES, PLAIN
- A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- Not Available
- PDB Entries
- Not Available
- FDA label
- Download (459 KB)
- MSDS
- Download (182 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers 3 1 Completed Treatment Renal Colic 1 2 Completed Treatment Colic 1 2 Completed Treatment Gastrointestinal Diseases 1 2, 3 Completed Prevention Endoscopy 1 3 Completed Prevention Bile Duct Diseases / ERCP / Pancreatic Diseases 1 3 Completed Treatment Intestinal Diseases 1 3 Recruiting Treatment Acute Abdomen / Children 1 3 Recruiting Treatment Prolonged Labour 1 4 Completed Prevention Family Planning 1 4 Completed Prevention Pain Relief With HSG 1 4 Completed Treatment Emergency / Indigestion / Pain 1 4 Completed Treatment Vaginal Delivery 1 4 Recruiting Supportive Care Vaginal Delivery 1 4 Recruiting Treatment Abdominal Cramps 1 Not Available Recruiting Diagnostic Constipation - Functional / Irritable Bowel Syndrome Characterized by Constipation 1 Not Available Recruiting Diagnostic Gastrointestinal Imaging With pCLE 1 Not Available Unknown Status Treatment Infertilities 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Liquid Intramuscular; Intravenous; Subcutaneous 20 mg Tablet Oral 10 mg Suppository Rectal 10 mg Solution Intramuscular; Intravenous; Subcutaneous 20 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00166 mg/mL ALOGPS logP -0.6 ALOGPS logP -1.9 ChemAxon logS -5.4 ALOGPS pKa (Strongest Acidic) 15.15 ChemAxon pKa (Strongest Basic) -2.7 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 59.06 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 109.51 m3·mol-1 ChemAxon Polarizability 39.88 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Beta hydroxy acids and derivatives
- Direct Parent
- Beta hydroxy acids and derivatives
- Alternative Parents
- Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Epoxides / Dialkyl ethers show 9 more
- Substituents
- Beta-hydroxy acid / Monocyclic benzene moiety / Oxazinane / Piperidine / Morpholine / N-alkylpyrrolidine / Benzenoid / Tetraalkylammonium salt / Pyrrolidine / Quaternary ammonium salt show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]
Drug created on November 10, 2015 13:46 / Updated on October 02, 2017 06:15